Migraine, allodynia, and implications for treatment
- 12 November 2008
- journal article
- review article
- Published by Wiley in European Journal of Neurology
- Vol. 15 (12), 1279-1285
- https://doi.org/10.1111/j.1468-1331.2008.02343.x
Abstract
Allodynia – perception of pain from non‐noxious stimuli – is a common clinical feature in various pain syndromes. The significance for migraine has increasingly been recognized and the pathophysiology has been investigated in detail. Allodynia is a marker for sensitization of central trigeminal neurons. Intensity and persistence of allodynic symptoms are a function of duration of migraine attacks, frequency of attacks, and migraine history. It has been hypothesized that treatment success with triptans may be severely impaired in the presence of allodynia. However, randomized controlled trials did not confirm that. Treatment with cyclooxygenase inhibitors and dihydroergotamine does not seem to be limited by allodynia; these medications may be able to reverse allodynia. Data on the new class of calcitonin‐gene related‐peptide antagonists are not yet available. Additional and more refined randomized controlled trials, focusing on methodological issues pertaining to the determination of allodynia, are warranted to resolve the true relationship between allodynia and treatment response. Regardless – based on available randomized controlled trials – the recommendation prevails to initiate abortive treatment as soon as possible after attack onset when pain is still mild.Keywords
This publication has 65 references indexed in Scilit:
- Difference in Triptan Effect in Patients With Migraine and Early AllodyniaCephalalgia, 2008
- Prevalence and characteristics of allodynia in headache sufferersNeurology, 2008
- Cutaneous allodynia in the migraine populationAnnals of Neurology, 2008
- Sensitization of meningeal nociceptors: inhibition by naproxenEuropean Journal of Neuroscience, 2008
- Sensitization of central trigeminovascular neurons: Blockade by intravenous naproxen infusionNeuroscience, 2007
- Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptansThe Journal of Headache and Pain, 2007
- Terminating Migraine With Allodynia and Ongoing Central Sensitization Using Parenteral Administration of COX1/COX2 InhibitorsHeadache: The Journal of Head and Face Pain, 2005
- The Effects of Greater Occipital Nerve Block and Trigger Point Injection on Brush Allodynia and Pain in MigraineHeadache: The Journal of Head and Face Pain, 2005
- Defeating migraine pain with triptans: A race against the development of cutaneous allodyniaAnnals of Neurology, 2003
- Neuronal Plasticity: Increasing the Gain in PainScience, 2000